Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?
- 31 March 1997
- journal article
- review article
- Published by Elsevier in Leukemia Research
- Vol. 21 (3) , 183-188
- https://doi.org/10.1016/s0145-2126(96)00075-6
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related ToxicitiesJournal of Liposome Research, 1993
- Development, Characterization, Efficacy and Mode of Action of Ambisome, A Unilamellar Liposomal Formulation of Amphotericin BJournal of Liposome Research, 1993
- Amphotericin B Formulated in Liposomes and Lipid Based Systems: A ReviewJournal of Liposome Research, 1993
- Fungal infections in cancer patients: An international autopsy surveyEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discsInternational Journal of Pharmaceutics, 1991
- Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to ratsAntimicrobial Agents and Chemotherapy, 1991
- Fungemia Caused by Candida Species and Torulopsis glabrata in the Hospitalized Patient: Frequency, Characteristics, and Evaluation of Factors Influencing OutcomeClinical Infectious Diseases, 1989
- Candida: An Increasingly Important Pathogen in the NurseryPediatric Clinics of North America, 1988
- Fungal Sepsis in Surgical PatientsArchives of Surgery, 1983
- Effects of Sterols on the Therapeutic Efficacy of Liposomal Amphotericin B in Murine CandidiasisCancer Drug Delivery, 1983